What does BioNexus Gene Lab's Form 3 filing reveal about Fidelion Diagnostics Pte. Ltd.'s ownership stake as of November 28, 2025?

BioNexus Gene Lab's Form 3 filing reveals that Fidelion Diagnostics Pte. Ltd. beneficially owns 392,329 common shares as of November 28, 2025, and is therefore identified as a greater-than-5% holder in BioNexus Gene Lab. The filing, signed by Ling Xiao on August 4, 2026, reports no derivative securities.

BioNexus Gene Lab Files Initial Beneficial Ownership Statement for Fidelion Diagnostics Pte. Ltd

Q: Who signed BioNexus Gene Lab's initial beneficial ownership statement for Fidelion Diagnostics, and what type of SEC form was filed?

Ling Xiao signed BioNexus Gene Lab's initial beneficial ownership statement for Fidelion Diagnostics Pte. Ltd., and the company filed a Form 3 with the U.S. Securities and Exchange Commission. This filing identifies Fidelion Diagnostics as a greater-than-5% holder owning 392,329 common shares as of November 28, 2025, and reports no derivative securities.

Aug 7, 2026

BioNexus Gene Lab Corp filed a Form 3 statement revealing Fidelion Diagnostics Pte. Ltd holds over 5% of common shares. The filing identifies Fidelion as a greater-than-5% holder with 392,329 shares as of November 28, 2025.

Bitget

BioNexus Gene Lab Files Initial Beneficial Ownership Statement for Fidelion Diagnostics

Bitget

BioNexus Gene Lab Files Initial Beneficial Ownership Statement for Fidelion Diagnostics Pte. Ltd

Bitget

2026-02-23

BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman

2026-03-12

BioNexus Gene Lab Corp. Appoints Dr. Muthu Meyyappan as CCO of Fidelion Diagnostics to Lead VitaGuard™ MRD Commercialization

2026-04-04

BioNexus Gene Lab Corp Stock Drops 3% on Poor Ratings